Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.

@article{Takahashi2014CombinedAO,
  title={Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.},
  author={Naoki Takahashi and Yasuhide Yamada and Hirokazu Taniguchi and Yoshitaka Honma and Satoru Iwasa and Ken Kato and Tetsuya Hamaguchi and Yasuhiro Shimada},
  journal={Archives of medical research},
  year={2014},
  volume={45 5},
  pages={366-74}
}
BACKGROUND AND AIMS Biomarkers associated with anti-EGFR antibodies therapy have been investigated in metastatic colorectal cancer (CRC). We conducted this study to evaluate the clinical utility of a combined assessment of EGFR status and genomic mutations of the EGFR downstream signal pathway in predicting the efficacy of anti-EGFR antibody treatment. METHODS We collected formalin-fixed paraffin-embedded tumor tissues and evaluated the EGFR status by immunohistochemistry (IHC), dual color in… CONTINUE READING